Johnson & Johnson: Schizophrenia trials

The registry lists 206 Schizophrenia studies with Johnson & Johnson as lead sponsor. 2 are open to participants now and 57 have results posted.

Early Phase 1 3Phase 1 40Phase 2 12Phase 3 74Phase 4 47No phase 31(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of an Anti-Psychotic in Patients With SchizophreniaCompletedNCT00074477Phase 2
• Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With SchizophreniaCompletedNCT00073320Phase 3
• Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of SchizophreniaCompletedNCT00063297Phase 2
• Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective DisorderCompletedNCT00061802Phase 4
• A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.CompletedNCT00034775Phase 3
• The Efficacy and Safety of Risperidone in the Treatment of Adolescents With SchizophreniaCompletedNCT00034749Phase 3